Compounds > emtricitabine, tenofovir disoproxil fumarate drug combination
Page last updated: 2024-08-02 22:23:55
emtricitabine, tenofovir disoproxil fumarate drug combination
Description
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination: A pharmaceutical preparation of emtricitabine and tenofovir that is used as an ANTI-HIV AGENT in the treatment and prevention of HIV INFECTIONS. [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 11954236 |
| SCHEMBL ID | 17373214 |
| MeSH ID | M000605888 |
Synonyms (15)
| Synonym |
|---|
| emtricitabine / tenofovir disoproxil fumarate |
| emtricitabine and tenofovir disoproxil fumarate |
| emtricitabine, tenofovir disoproxil fumarate drug combination |
| tenofovir disoproxil fumarate/emtricitabine |
| emtricitabine and tenofovir |
| 731772-45-5 |
| emtricitabine / tenofovir |
| tenofovir / emtricitabine |
| SCHEMBL17373214 |
| emtricitabine tenofovir df |
| VERWQPYQDXWOGT-LVJNJWHOSA-N |
| emtricitabine tenofovir disoproxil fumarate |
| Q2412859 |
| tenofovir/emtricitabine |
| 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid |
Research
Studies (239)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (8.37) | 29.6817 |
| 2010's | 191 (79.92) | 24.3611 |
| 2020's | 28 (11.72) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 31 (12.20%) | 5.53% |
| Reviews | 25 (9.84%) | 6.00% |
| Case Studies | 14 (5.51%) | 4.05% |
| Observational | 4 (1.57%) | 0.25% |
| Other | 180 (70.87%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2005 | 2021 | 11.3 | low | 2 | 0 | 0 | 9 | 15 | 2 |
| albendazole | | aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester | anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nevirapine | | cyclopropanes;
dipyridodiazepine | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2011 | 2016 | 10.6 | low | 2 | 0 | 0 | 0 | 5 | 0 |
| probenecid | | benzoic acids;
sulfonamide | uricosuric drug | 2020 | 2020 | 4.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| pyrimethamine | | aminopyrimidine;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alanine | | alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid | EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite | 2012 | 2021 | 5.7 | low | 1 | 0 | 0 | 0 | 4 | 2 |
| carbostyril | | monohydroxyquinoline;
quinolone | bacterial xenobiotic metabolite | 2009 | 2010 | 14.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methamphetamine | | amphetamines;
secondary amine | central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic | 2018 | 2023 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| deoxycytidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2004 | 2015 | 12.5 | medium | 4 | 0 | 0 | 26 | 75 | 0 |
| stavudine | | dihydrofuran;
nucleoside analogue;
organic molecular entity | antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cetylpyridinium chloride anhydrous | | chloride salt;
organic chloride salt | antiseptic drug;
surfactant | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| zidovudine | | azide;
pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2007 | 2020 | 11.0 | low | 1 | 0 | 0 | 2 | 5 | 0 |
| cidofovir anhydrous | | phosphonic acids;
pyrimidone | anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| lamivudine | | monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol | allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2004 | 2022 | 12.8 | low | 2 | 0 | 0 | 8 | 5 | 1 |
| emtricitabine | | monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2005 | 2023 | 8.0 | low | 2 | 0 | 0 | 4 | 9 | 8 |
| efavirenz | | acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2007 | 2020 | 9.6 | low | 3 | 0 | 0 | 1 | 4 | 0 |
| triazoles | | 1,2,3-triazole | | 2016 | 2017 | 7.5 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| lopinavir | | amphetamines;
dicarboxylic acid diamide | anticoronaviral agent;
antiviral drug;
HIV protease inhibitor | 2012 | 2017 | 9.5 | low | 2 | 0 | 0 | 0 | 6 | 0 |
| atazanavir sulfate | | organic sulfate salt | | 2010 | 2019 | 10.0 | low | 2 | 0 | 0 | 1 | 3 | 0 |
| combivir | | | | 2007 | 2020 | 10.6 | low | 1 | 0 | 0 | 2 | 3 | 0 |
| organophosphonates | | divalent inorganic anion;
phosphite ion | | 2005 | 2022 | 12.9 | low | 0 | 0 | 0 | 9 | 10 | 1 |
| darunavir | | carbamate ester;
furofuran;
sulfonamide | antiviral drug;
HIV protease inhibitor | 2014 | 2019 | 8.0 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| ritonavir | | 1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas | antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic | 2009 | 2021 | 9.4 | low | 4 | 0 | 0 | 2 | 11 | 1 |
| linezolid | | acetamides;
morpholines;
organofluorine compound;
oxazolidinone | antibacterial drug;
protein synthesis inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tenofovir | | nucleoside analogue;
phosphonic acids | antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor | 2005 | 2023 | 8.3 | low | 7 | 0 | 0 | 7 | 24 | 9 |
| maraviroc | | tropane alkaloid | | 2016 | 2017 | 7.5 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| abacavir, lamivudine drug combination | | | | 2004 | 2017 | 14.8 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| jtk-303 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | HIV-1 integrase inhibitor | 2009 | 2010 | 14.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| fumarates | | butenedioate;
C4-dicarboxylate | human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rilpivirine | | aminopyrimidine;
nitrile | EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor | 2009 | 2022 | 10.3 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| gs-7340 | | 6-aminopurines;
ether;
isopropyl ester;
L-alanine derivative;
phosphoramidate ester | antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2012 | 2021 | 5.7 | low | 1 | 0 | 0 | 0 | 4 | 2 |
| efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination | | | | 2009 | 2012 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| raltegravir potassium | | | | 2008 | 2019 | 9.3 | low | 3 | 0 | 0 | 1 | 10 | 0 |
| ro13-9904 | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| combivent respimat | | | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| cobicistat | | 1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas | P450 inhibitor | 2019 | 2021 | 4.0 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| quad pill | | | | 2018 | 2022 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| sofosbuvir | | isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester | antiviral drug;
hepatitis C protease inhibitor;
prodrug | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk1265744 | | difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide | HIV-1 integrase inhibitor | 2015 | 2021 | 5.0 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| dolutegravir | | difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide | HIV-1 integrase inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levoleucovorin | | 5-formyltetrahydrofolic acid | antineoplastic agent;
metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sildenafil citrate | | citrate salt | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| 2019 Novel Coronavirus Disease | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Abnormalities, Congenital, Nervous System | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acquired Immune Deficiency Syndrome | 0 | | 2004 | 2023 | 8.8 | low | 1 | 0 | 0 | 1 | 6 | 1 |
| Acquired Immunodeficiency Syndrome | 0 | | 2004 | 2023 | 8.8 | low | 1 | 0 | 0 | 1 | 6 | 1 |
| Acquired-Immune Deficiency Syndrome Dementia Complex | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Disease | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Liver Injury, Drug-Induced | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| AIDS Dementia Complex | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| AIDS Seroconversion | 0 | | 2013 | 2021 | 6.3 | low | 1 | 0 | 0 | 0 | 5 | 1 |
| AIDS-Related Opportunistic Infections | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| AIDS, Simian | 0 | | 2010 | 2020 | 10.5 | low | 0 | 0 | 0 | 1 | 10 | 0 |
| Allergy, Drug | 0 | | 2005 | 2007 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Arrhythmia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Arrhythmias, Cardiac | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Autoimmune Disease | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Autoimmune Diseases | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Autoimmune Diseases of the Nervous System | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bacterial Sexually Transmitted Disease | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bacterial Vaginitides | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Biliary Cirrhosis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bone Diseases | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Ovary | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carditis | 0 | | 2011 | 2015 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Central Nervous System Toxoplasmosis | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chemical Dependence | 0 | | 2016 | 2019 | 6.5 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Chlamydia Infections | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cholangitis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cholera Infantum | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Disease | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Hepatitis B | 0 | | 2015 | 2016 | 8.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Chronic Hepatitis C | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Illness | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Insomnia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Co-infection | 0 | | 2013 | 2019 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Cognition Disorders | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Coma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Communicable Diseases | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Complications, Infectious Pregnancy | 0 | | 2016 | 2018 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Congenital Zika Syndrome | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Coronavirus Infections | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Dermatitis, Atopic | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Disease Models, Animal | 0 | | 2010 | 2020 | 8.7 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| Diseases, Occupational | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drug Hypersensitivity | 0 | | 2005 | 2007 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Ebola Hemorrhagic Fever | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Eczema, Atopic | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Edema, Pulmonary | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Esophagitis | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Fibroma, Shope | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Genital Herpes | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Great Pox | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hemorrhagic Fever, Ebola | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hepatitis B | 0 | | 2015 | 2022 | 6.2 | low | 0 | 0 | 0 | 0 | 3 | 2 |
| Hepatitis B Virus Infection | 0 | | 2015 | 2022 | 6.2 | low | 0 | 0 | 0 | 0 | 3 | 2 |
| Hepatitis B, Chronic | 0 | | 2015 | 2016 | 8.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Hepatitis C | 0 | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Hepatitis C, Chronic | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted | 0 | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Herpes Genitalis | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| HIV | 0 | | 2009 | 2021 | 9.8 | low | 2 | 0 | 0 | 3 | 7 | 2 |
| HIV Coinfection | 0 | | 2004 | 2023 | 8.8 | high | 27 | 0 | 0 | 22 | 172 | 17 |
| HIV Infections | 0 | | 2004 | 2023 | 8.8 | high | 27 | 0 | 0 | 22 | 172 | 17 |
| Infections, Chlamydia | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Coronavirus | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Retroviridae | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infectious Diseases | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Injuries, Needlestick | 0 | | 2014 | 2017 | 8.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Kidney Diseases | 0 | | 2016 | 2018 | 7.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Kidney Failure | 0 | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Libman-Sacks Disease | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lipodystrophy | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Cirrhosis, Biliary | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lupus Erythematosus, Systemic | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscle Disorders | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscular Diseases | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myocarditis | 0 | | 2011 | 2015 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Ovarian Neoplasms | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pneumonia, Viral | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pregnancy | 0 | | 2013 | 2021 | 7.0 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| Pulmonary Edema | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Renal Insufficiency | 0 | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Retroviridae Infections | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sexually Transmitted Diseases | 0 | | 2012 | 2017 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Sexually Transmitted Diseases, Bacterial | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Skin Syphilis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sleep Initiation and Maintenance Disorders | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Substance-Related Disorders | 0 | | 2016 | 2019 | 6.5 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Syphilis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Toxoplasmosis, Cerebral | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Trichomonas Vaginitis | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Trichomoniasis, Human | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Vaginosis, Bacterial | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Viremia | 0 | | 2012 | 2015 | 11.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Zika Virus Infection | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy.Frontiers in public health, , Volume: 11, 2023
Long-acting drug acts like a short-term AIDS vaccine.Science (New York, N.Y.), , 05-22, Volume: 368, Issue:6493, 2020
Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.Journal of acquired immune deficiency syndromes (1999), , 09-01, Volume: 82, Issue:1, 2019
Extensive brain masses and cavitary lung lesions associated with toxoplasmosis and acquired immunodeficiency syndrome.International journal of STD & AIDS, , Volume: 28, Issue:11, 2017
Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.American journal of epidemiology, , Nov-15, Volume: 182, Issue:10, 2015
FDA must publish data on safety and efficacy of prophylactic AIDS drug, court rules.BMJ (Clinical research ed.), , Aug-19, Volume: 347, 2013
PrEP trial successes prompt cost-effectiveness questions.Nature medicine, , Sep-07, Volume: 17, Issue:9, 2011
FDA approves two combo brand-name AIDS drugs.Medicine & health (1997), , Aug-09, Volume: 58, Issue:31, 2004
A truvada hypersensitivity reaction simulating abacavir hypersensitivity.AIDS (London, England), , Oct-18, Volume: 21, Issue:16, 2007
Two-once-daily fixed-dose NRTI combinations for HIV.The Medical letter on drugs and therapeutics, , Feb-28, Volume: 47, Issue:1203, 2005
Comparison of 3-drug versus 4-drug and PI versus non-PI combinations as initial HAART: experience from 1998 to 2007.Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), , Volume: 8, Issue:5
The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.Viruses, , 09-07, Volume: 14, Issue:9, 2022
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.Viruses, , 12-02, Volume: 13, Issue:12, 2021
Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies.Reproductive biomedicine online, , Volume: 33, Issue:2, 2016
[A needlestick injury - what next?].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.Journal of medical case reports, , Sep-28, Volume: 9, 2015
[no title available]Zentralblatt fur Chirurgie, , Volume: 142, Issue:4, 2017
Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies.Reproductive biomedicine online, , Volume: 33, Issue:2, 2016
[A needlestick injury - what next?].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Achilles heel spotted for promising HIV-prevention drug.Nature, , Volume: 591, Issue:7850, 2021
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.Viruses, , 12-02, Volume: 13, Issue:12, 2021
Readability analysis of online health information on preexposure prophylaxis (PrEP).Public health, , Volume: 182, 2020
Recent advances in pre-exposure prophylaxis for HIV.BMJ (Clinical research ed.), , 12-11, Volume: 359, 2017
Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.Journal of acquired immune deficiency syndromes (1999), , Apr-01, Volume: 71, Issue:4, 2016
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Medicinal research reviews, , Volume: 32, Issue:4, 2012
AIDS research. FDA panel recommends anti-HIV drug for prevention.Science (New York, N.Y.), , May-18, Volume: 336, Issue:6083, 2012
Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.Antiviral therapy, , Volume: 17, Issue:6, 2012
Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.Journal of virology, , Volume: 85, Issue:15, 2011
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.Expert review of clinical immunology, , Volume: 6, Issue:2, 2010
HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.Science (New York, N.Y.), , Dec-03, Volume: 330, Issue:6009, 2010
Truvada and Epivir are similar at suppressing HIV.Project Inform perspective, , Issue:48, 2009
Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.Expert opinion on drug safety, , Volume: 20, Issue:11, 2021
Role of Preexposure Prophylaxis in the Reproductive Health of Women at Risk for Human Immunodeficiency Virus Infection.Obstetrics and gynecology, , Volume: 132, Issue:3, 2018
Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies.Reproductive biomedicine online, , Volume: 33, Issue:2, 2016
Using registries to monitor HIV pre-exposure prophylaxis safety in clinical settings.American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy.Frontiers in public health, , Volume: 11, 2023
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously Estimated.Health affairs (Project Hope), , Volume: 42, Issue:5, 2023
Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 01-06, Volume: 76, Issue:1, 2023
HIV Prevention Research Experiences Among Men Who Have Sex With Men and Transgender Persons of Color.Journal of racial and ethnic health disparities, , Volume: 10, Issue:4, 2023
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide.AIDS (London, England), , 12-01, Volume: 36, Issue:15, 2022
The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.Viruses, , 09-07, Volume: 14, Issue:9, 2022
Pill related oesophagitis due to tenofovir disproxil fumarate/emtricitabine (Truvada) HIV pre-exposure prophylaxis.Internal medicine journal, , Volume: 52, Issue:6, 2022
Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.International journal of antimicrobial agents, , Volume: 59, Issue:1, 2022
Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?AIDS patient care and STDs, , Volume: 35, Issue:8, 2021
The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.The Pan African medical journal, , Volume: 38, 2021
Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.Expert opinion on drug safety, , Volume: 20, Issue:11, 2021
Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.Drug testing and analysis, , Volume: 13, Issue:7, 2021
Achilles heel spotted for promising HIV-prevention drug.Nature, , Volume: 591, Issue:7850, 2021
Primary HIV-1 infection in users of pre-exposure prophylaxis.The lancet. HIV, , Volume: 8, Issue:3, 2021
Effect of Truvada lawsuit advertising on preexposure prophylaxis attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV.AIDS (London, England), , 01-01, Volume: 35, Issue:1, 2021
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.Viruses, , 12-02, Volume: 13, Issue:12, 2021
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.Lancet (London, England), , 07-25, Volume: 396, Issue:10246, 2020
Renal impairment: an unnecessary barrier to HIV prevention.Sexual health, , Volume: 17, Issue:3, 2020
Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.Expert opinion on drug metabolism & toxicology, , Volume: 16, Issue:6, 2020
Readability analysis of online health information on preexposure prophylaxis (PrEP).Public health, , Volume: 182, 2020
How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States?Annals of internal medicine, , 05-05, Volume: 172, Issue:9, 2020
The HIV Pre-exposure Prophylaxis (PrEP) Cascade at NYC Sexual Health Clinics: Navigation Is the Key to Uptake.Journal of acquired immune deficiency syndromes (1999), , 04-01, Volume: 83, Issue:4, 2020
Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.CPT: pharmacometrics & systems pharmacology, , Volume: 9, Issue:1, 2020
[Progression of STI noted after initiation of EPESE for HIV].Annales de dermatologie et de venereologie, , Volume: 146, Issue:10, 2019
Ethical considerations for new HIV prevention trials.The lancet. HIV, , Volume: 6, Issue:8, 2019
Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.Journal of acquired immune deficiency syndromes (1999), , 09-01, Volume: 82, Issue:1, 2019
HIV preexposure prophylaxis in Canadian primary care and community settings.Canadian family physician Medecin de famille canadien, , Volume: 65, Issue:4, 2019
Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.Pharmacotherapy, , Volume: 39, Issue:4, 2019
Access to HIV Pre-exposure Prophylaxis in Practice Settings: a Qualitative Study of Sexual and Gender Minority Adults' Perspectives.Journal of general internal medicine, , Volume: 34, Issue:4, 2019
Mg-supplementation attenuated lipogenic and oxidative/nitrosative gene expression caused by Combination Antiretroviral Therapy (cART) in HIV-1-transgenic rats.PloS one, , Volume: 14, Issue:1, 2019
Some men who were unable to access PrEP through NHS trial are now HIV positive, charities report.BMJ (Clinical research ed.), , Jan-18, Volume: 364, 2019
Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.PloS one, , Volume: 14, Issue:1, 2019
Experiences of Anticipated and Enacted Pre-exposure Prophylaxis (PrEP) Stigma Among Latino MSM in Los Angeles.AIDS and behavior, , Volume: 23, Issue:7, 2019
Informal PrEP: an emerging need for nomenclature.The Lancet. Public health, , Volume: 4, Issue:2, 2019
Early experience of implementing a national HIV pre-exposure prophylaxis service in Wales, United Kingdom 2017.Sexual health, , Volume: 16, Issue:1, 2019
A Randomized Controlled Pilot Study of a Culturally-Tailored Counseling Intervention to Increase Uptake of HIV Pre-exposure Prophylaxis Among Young Black Men Who Have Sex with Men in Washington, DC.AIDS and behavior, , Volume: 23, Issue:1, 2019
Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.AIDS and behavior, , Volume: 23, Issue:2, 2019
Atypical secondary syphilis presentation in a patient with human immunodeficiency virus infection: a case report.Journal of medical case reports, , Dec-09, Volume: 13, Issue:1, 2019
Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants.The International journal on drug policy, , Volume: 74, 2019
Piloting a partially self-financed mode of human immunodeficiency virus pre-exposure prophylaxis delivery for men who have sex with men in Hong Kong.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 25, Issue:5, 2019
Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.PloS one, , Volume: 14, Issue:8, 2019
Are 2 million bottles of PrEP an empty gesture?The lancet. HIV, , Volume: 6, Issue:8, 2019
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/Antiviral research, , Volume: 170, 2019
Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.HIV clinical trials, , Volume: 19, Issue:5, 2018
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.The lancet. HIV, , Volume: 5, Issue:11, 2018
Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine.Journal of managed care & specialty pharmacy, , Volume: 24, Issue:10, 2018
Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States.Annals of epidemiology, , Volume: 28, Issue:12, 2018
HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise.Clinical pharmacology and therapeutics, , Volume: 104, Issue:6, 2018
Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.Clinical pharmacology and therapeutics, , Volume: 104, Issue:6, 2018
PrEP and the PrEPstars.The lancet. HIV, , Volume: 5, Issue:11, 2018
Role of Preexposure Prophylaxis in the Reproductive Health of Women at Risk for Human Immunodeficiency Virus Infection.Obstetrics and gynecology, , Volume: 132, Issue:3, 2018
"Free Testing and PrEP without Outing Myself to Parents:" Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men.PloS one, , Volume: 13, Issue:7, 2018
Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.Annals of epidemiology, , Volume: 28, Issue:12, 2018
The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.Annals of epidemiology, , Volume: 28, Issue:12, 2018
How to do it: setting up a PrEP service in an integrated sexual reproductive health service setting.Sexually transmitted infections, , Volume: 94, Issue:5, 2018
Geographic and Individual Associations with PrEP Stigma: Results from the RADAR Cohort of Diverse Young Men Who have Sex with Men and Transgender Women.AIDS and behavior, , Volume: 22, Issue:9, 2018
Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City.AIDS and behavior, , Volume: 22, Issue:11, 2018
Truvada (emtricitabine/tenofovir) pre-exposure prophylaxis roll-out among South African university students: Lots of positives, but let us keep an eye on possible surprises.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, , Feb-01, Volume: 108, Issue:2, 2018
HIV Prevention Drug's Slow Uptake Undercuts Its Early Promise.Health affairs (Project Hope), , Volume: 37, Issue:2, 2018
The informal use of antiretroviral medications for HIV prevention by men who have sex with men in South Florida: initiation, use practices, medications and motivations.Culture, health & sexuality, , Volume: 20, Issue:11, 2018
Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa.AIDS and behavior, , Volume: 22, Issue:7, 2018
Science, technology, power and sex: PrEP and HIV-positive gay men in Paris.Culture, health & sexuality, , Volume: 19, Issue:10, 2017
A case study of chewed TruvadaAntiviral therapy, , Volume: 22, Issue:7, 2017
Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis.Journal of acquired immune deficiency syndromes (1999), , 07-01, Volume: 75, Issue:3, 2017
Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.The New England journal of medicine, , 02-02, Volume: 376, Issue:5, 2017
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.Drug safety, , Volume: 40, Issue:4, 2017
Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men.AIDS and behavior, , Volume: 21, Issue:5, 2017
Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.AIDS and behavior, , Volume: 21, Issue:2, 2017
PrEP on Twitter: Information, Barriers, and Stigma.Health communication, , Volume: 32, Issue:4, 2017
Recent advances in pre-exposure prophylaxis for HIV.BMJ (Clinical research ed.), , 12-11, Volume: 359, 2017
Regimen Change: Gilead's TAF Drugs Toppling TDFs in HIV Treatment.Managed care (Langhorne, Pa.), , Volume: 26, Issue:9, 2017
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis.Colombia medica (Cali, Colombia), , Jun-30, Volume: 48, Issue:2, 2017
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.Journal of acquired immune deficiency syndromes (1999), , 12-15, Volume: 76, Issue:5, 2017
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.JAMA pediatrics, , 11-01, Volume: 171, Issue:11, 2017
HIV preexposure prophylaxis for adolescents and young adults.Current opinion in pediatrics, , Volume: 29, Issue:4, 2017
Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:7, 2017
Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa.Culture, health & sexuality, , Volume: 19, Issue:11, 2017
Scotland's approval of PrEP creates postcode lottery in UK, say campaigners.BMJ (Clinical research ed.), , 04-11, Volume: 357, 2017
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).The Journal of antimicrobial chemotherapy, , 06-01, Volume: 72, Issue:6, 2017
PrEP, Truvada, and Gilead.BMJ (Clinical research ed.), , Sep-08, Volume: 354, 2016
Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Expert opinion on drug safety, , Volume: 15, Issue:9, 2016
[EMA examines an application for change in authorization of truvada].MMW Fortschritte der Medizin, , Jun-09, Volume: 158 Suppl 1, 2016
[Protection against HIV - but only with good compliance!].MMW Fortschritte der Medizin, , Jun-09, Volume: 158 Suppl 1, 2016
Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies.Reproductive biomedicine online, , Volume: 33, Issue:2, 2016
Sharing of Investigational Drug Among Participants in the Voice Trial.AIDS and behavior, , Volume: 20, Issue:11, 2016
HIV moments and pre-exposure prophylaxis--Authors' reply.Lancet (London, England), , Apr-09, Volume: 387, Issue:10027, 2016
HIV moments and pre-exposure prophylaxis.Lancet (London, England), , Apr-09, Volume: 387, Issue:10027, 2016
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.AIDS research and therapy, , Volume: 13, 2016
Pre-exposure Prophylaxis in Primary Care--A New Era in HIV Prevention.WMJ : official publication of the State Medical Society of Wisconsin, , Volume: 115, Issue:1, 2016
Feasibility of HIV Pre-Exposure Prophylaxis as Part of Routine Care in Toronto, Canada.Journal of acquired immune deficiency syndromes (1999), , 07-01, Volume: 72, Issue:3, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.Trials, , Mar-24, Volume: 17, 2016
Uncertainty in Online U.S. News Coverage of Truvada.Health communication, , Volume: 31, Issue:10, 2016
[HIV pre-exposure prophylaxis does not increase the rate of STI].Revue medicale suisse, , Jan-27, Volume: 12, Issue:503, 2016
Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.Journal of acquired immune deficiency syndromes (1999), , Apr-01, Volume: 71, Issue:4, 2016
Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?AIDS and behavior, , Volume: 20, Issue:11, 2016
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.PLoS pathogens, , Volume: 12, Issue:1, 2016
ACP Journal Club. Preexposure tenofovir-emtricitabine reduced HIV infection in men who have unprotected anal sex with men.Annals of internal medicine, , Jan-19, Volume: 164, Issue:2, 2016
Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.The Journal of infectious diseases, , May-15, Volume: 213, Issue:10, 2016
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.Clinical pharmacokinetics, , Volume: 55, Issue:7, 2016
The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.Current opinion in HIV and AIDS, , Volume: 11, Issue:1, 2016
Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.Journal of acquired immune deficiency syndromes (1999), , Apr-01, Volume: 71, Issue:4, 2016
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.Lancet (London, England), , Jan-02, Volume: 387, Issue:10013, 2016
Antiretroviral chemoprophylaxis: PROUD and pragmatism.Lancet (London, England), , Jan-02, Volume: 387, Issue:10013, 2016
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.Antiviral therapy, , Volume: 21, Issue:3, 2016
[no title available]Revue medicale suisse, , Aug-10, Volume: 12, Issue:526, 2016
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.Journal of acquired immune deficiency syndromes (1999), , 03-01, Volume: 71, Issue:3, 2016
[HIV: France authorizes and fully reimburses Truvada prophylaxis].Revue medicale suisse, , Dec-02, Volume: 11, Issue:497, 2015
[Miscellaneous - profound coma, smoking and AIDS].Revue medicale suisse, , Nov-18, Volume: 11, Issue:495, 2015
HOW DO I PAY FOR PrEP?Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 27, Issue:5, 2015
MOVING FORWARD WITH PrEP. THE BASICS OF PrEP.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 27, Issue:5, 2015
Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.American journal of epidemiology, , Nov-15, Volume: 182, Issue:10, 2015
Invited commentary: every good randomization deserves observation.American journal of epidemiology, , Nov-15, Volume: 182, Issue:10, 2015
Murnane, Coley, and Baeten respond to "every good randomization deserves observation".American journal of epidemiology, , Nov-15, Volume: 182, Issue:10, 2015
Infection: PrEParation to be PROUD of.Nature reviews. Urology, , Volume: 12, Issue:11, 2015
Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis.Culture, health & sexuality, , Volume: 17, Issue:4, 2015
How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores".American journal of public health, , Volume: 105, Issue:10, 2015
CDC launches prevention efforts focused on PrEP, high-risk groups.AIDS policy & law, , Volume: 30, Issue:6, 2015
Acute Myocarditis and Myopathy as Presenting Manifestations of Human Immunodeficiency Virus Infection.The Israel Medical Association journal : IMAJ, , Volume: 17, Issue:8, 2015
Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.PloS one, , Volume: 10, Issue:10, 2015
Tailoring biomedical interventions for key populations.The lancet. HIV, , Volume: 2, Issue:1, 2015
[Should pre-exposure prophylaxis be used to prevent HIV?].Revue medicale suisse, , Mar-11, Volume: 11, Issue:465, 2015
Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.Journal of acquired immune deficiency syndromes (1999), , Aug-01, Volume: 69, Issue:4, 2015
Infectious diseases. Doubts dispelled about HIV prevention.Science (New York, N.Y.), , Mar-06, Volume: 347, Issue:6226, 2015
Willingness to Take PrEP and Potential for Risk Compensation Among Highly Sexually Active Gay and Bisexual Men.AIDS and behavior, , Volume: 19, Issue:12, 2015
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.AIDS (London, England), , May-15, Volume: 29, Issue:8, 2015
Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.Journal of medical case reports, , Sep-28, Volume: 9, 2015
Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.Current HIV/AIDS reports, , Volume: 11, Issue:4, 2014
The medicalization of HIV prevention: new opportunities beset by old challenges.The Milbank quarterly, , Volume: 92, Issue:3, 2014
Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults.The Nurse practitioner, , Sep-18, Volume: 39, Issue:9, 2014
A combination drug for HIV prevention in high-risk groups.The American journal of nursing, , Volume: 114, Issue:8, 2014
The Truvada wars.BMJ (Clinical research ed.), , Jun-24, Volume: 348, 2014
Miriam Hospital launches new HIV prevention program: PrEP program offers daily pill that can help prevent HIV infection.Rhode Island medical journal (2013), , Volume: 97, Issue:1, 2014
Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.PharmacoEconomics, , Volume: 32, Issue:9, 2014
CDC promotes pre-exposure prophylaxis for HIV prevention.BMJ (Clinical research ed.), , May-19, Volume: 348, 2014
Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 58, Issue:12, 2014
Reply to Sachdev et al.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 58, Issue:12, 2014
Potential HIV prophylaxis enters Canadian pilot trial.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , May-13, Volume: 186, Issue:8, 2014
Uptake of PrEP for HIV slow among MSM.Lancet (London, England), , Feb-01, Volume: 383, Issue:9915, 2014
Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 58, Issue:5, 2014
[HIV prophylaxis kits. A concept for emergency treatment in the context of postexposure prophylaxis].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, , Volume: 85, Issue:1, 2014
From efficacy to impact: an advocate's agenda for HIV pre-exposure prophylaxis implementation.American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Pre-exposure prophylaxis for HIV: who will benefit and what are the challenges?American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Pre-exposure prophylaxis for HIV: can it be implemented in the real world?American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Using registries to monitor HIV pre-exposure prophylaxis safety in clinical settings.American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance.American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand.AIDS care, , Volume: 25, Issue:8, 2013
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.Journal of acquired immune deficiency syndromes (1999), , Feb-01, Volume: 62, Issue:2, 2013
High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.AIDS and behavior, , Volume: 17, Issue:6, 2013
An equal right to protection.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
PrEP in practice.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
PrEP in the real world.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
From professional to personal.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
The new revolution: HIV prevention in a pill.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.American family physician, , Oct-15, Volume: 88, Issue:8, 2013
[PrEP approved in the USA: facts and discussion - permanent chemoprophylaxis for healthy people].MMW Fortschritte der Medizin, , Jun-13, Volume: 155 Suppl 1, 2013
Emtricitabine + tenofovir to prevent HIV transmission. More evaluation needed.Prescrire international, , Volume: 22, Issue:140, 2013
From modeling to morals: imagining the future of HIV PREP in Lesotho.Developing world bioethics, , Volume: 13, Issue:2, 2013
PrEPPING for the future.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
PrEP politics.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.PloS one, , Volume: 7, Issue:12, 2012
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.PloS one, , Volume: 7, Issue:10, 2012
Truvada for HIV prophylaxis in heterosexual patients.JAAPA : official journal of the American Academy of Physician Assistants, , Volume: 25, Issue:10, 2012
A perspective on progress and gaps in HIV prevention science.AIDS research and human retroviruses, , Volume: 28, Issue:11, 2012
Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.Antiviral therapy, , Volume: 17, Issue:6, 2012
HIV pre-exposure prophylaxis.BMJ (Clinical research ed.), , Aug-13, Volume: 345, 2012
In brief: Truvada for HIV prevention.The Medical letter on drugs and therapeutics, , Aug-06, Volume: 54, Issue:1396, 2012
FDA paves the way for pre-exposure HIV prophylaxis.Lancet (London, England), , Jul-28, Volume: 380, Issue:9839, 2012
Ethical challenges of preexposure prophylaxis for HIV.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
Preexposure prophylaxis for HIV infection.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
[HIV preexposure prophylaxis].Przeglad epidemiologiczny, , Volume: 66, Issue:1, 2012
How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.The American journal of bioethics : AJOB, , Volume: 12, Issue:6, 2012
AIDS research. FDA panel recommends anti-HIV drug for prevention.Science (New York, N.Y.), , May-18, Volume: 336, Issue:6083, 2012
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Medicinal research reviews, , Volume: 32, Issue:4, 2012
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.AIDS (London, England), , Mar-13, Volume: 26, Issue:5, 2012
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.International journal of STD & AIDS, , Volume: 23, Issue:1, 2012
Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice.Antimicrobial agents and chemotherapy, , Volume: 56, Issue:4, 2012
FDA approves first drug to prevent HIV infection.BMJ (Clinical research ed.), , Jul-17, Volume: 345, 2012
Research. Approval of Gilead's Truvada for PrEP passes first hurdle at FDA.AIDS policy & law, , Volume: 27, Issue:8, 2012
FDA PrEPares to reduce risk of HIV infection with Truvada®.Expert review of clinical pharmacology, , Volume: 5, Issue:5, 2012
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.International journal of clinical practice, , Volume: 65, Issue:12, 2011
HIV drug-prevention strategy carries risks.Nature, , Aug-16, Volume: 476, Issue:7360, 2011
AIDS research. Complexity surrounds HIV prevention advances.Science (New York, N.Y.), , Jul-22, Volume: 333, Issue:6041, 2011
Transmission. Company halts Truvada PrEP for women study.AIDS policy & law, , Volume: 26, Issue:7, 2011
Interim guidance for PrEP in MSM. CDC: Do not expand to other risk groups yet.AIDS alert, , Volume: 26, Issue:4, 2011
Early end for FEM-PrEP HIV prevention trial.AIDS patient care and STDs, , Volume: 25, Issue:6, 2011
HIV prevention trial in women is abandoned after drugs show no impact on infection rates.BMJ (Clinical research ed.), , Apr-20, Volume: 342, 2011
Trial success spurs planning for rollout of HIV prevention pills.Nature medicine, , Volume: 17, Issue:4, 2011
Great results from iPrEx study add to trifecta of good news on prevention. Truvada PrEP provided protection in MSM+transgender.AIDS alert, , Volume: 26, Issue:1, 2011
HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.Science (New York, N.Y.), , Dec-03, Volume: 330, Issue:6009, 2010
Still a long wait for approved HIV-protective gel.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, , Sep-07, Volume: 100, Issue:9, 2010
Bioequivalent formulation for the fixed-dose regimen of Truvada and TMC278 finalized.AIDS patient care and STDs, , Volume: 24, Issue:6, 2010
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.Expert review of clinical immunology, , Volume: 6, Issue:2, 2010
Single-tablet Quad regimen achieves high rate of virologic suppression.AIDS patient care and STDs, , Volume: 24, Issue:3, 2010
Second complete once-daily single tablet therapy in development.AIDS patient care and STDs, , Volume: 23, Issue:8, 2009
Truvada and Epivir are similar at suppressing HIV.Project Inform perspective, , Issue:48, 2009
Tapping into combination pills for HIV.Nature reviews. Drug discovery, , Volume: 8, Issue:6, 2009
Generic Truvada approved.AIDS patient care and STDs, , Volume: 23, Issue:5, 2009
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, , Volume: 28, Issue:4, 2009
Switching Combivir to Truvada keeps HIV undetectable, improves blood fats, fails to improve limb fat.Project Inform perspective, , Issue:47, 2008
Gay community to test HIV prevention pill.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, , Volume: 98, Issue:9, 2008
Trial will evaluate a once-daily dose of raltegravir.AIDS patient care and STDs, , Volume: 22, Issue:11, 2008
Mexico conference considers pre-exposure prophylaxis for AIDS.BMJ (Clinical research ed.), , Aug-14, Volume: 337, 2008
HIV study yields unexpected preliminary efficacy results.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Apr-15, Volume: 65, Issue:8, 2008
A truvada hypersensitivity reaction simulating abacavir hypersensitivity.AIDS (London, England), , Oct-18, Volume: 21, Issue:16, 2007
144-week data released on Gilead's study 934.AIDS patient care and STDs, , Volume: 21, Issue:8, 2007
Truvada intolerance.AIDS (London, England), , Jan-30, Volume: 21, Issue:3, 2007
[Simply convincing. New fixed combination for HIV therapy].MMW Fortschritte der Medizin, , Apr-25, Volume: 147 Spec No 1, 2005
[New fixed combination for HIV therapy].Krankenpflege Journal, , Volume: 43, Issue:4-6, 2005
Two-once-daily fixed-dose NRTI combinations for HIV.The Medical letter on drugs and therapeutics, , Feb-28, Volume: 47, Issue:1203, 2005
Emtricitabine/tenofovir disoproxil fumarate.Drugs, , Volume: 64, Issue:18, 2004
PrEP'ing.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 24, Issue:5
Another blue pill for sex: Preventing HIV with Truvada PrEP--already at a pharmacy near you.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 23, Issue:5
PrEP trial in women halted due to doubts that it could show efficacy.IAVI report : newsletter on international AIDS vaccine research, , Volume: 15, Issue:2
The iPrEx results: lifting hopes, raising questions.BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, , Volume: 22, Issue:4
Comparison of 3-drug versus 4-drug and PI versus non-PI combinations as initial HAART: experience from 1998 to 2007.Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), , Volume: 8, Issue:5
Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.Internal medicine (Tokyo, Japan), , Volume: 55, Issue:23
Knee avascular necrosis in HIV patient.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 107, Issue:2
I Am Men's Health: Generating Adherence to HIV Pre-Exposure Prophylaxis (PrEP) in Young Men of Color Who Have Sex with Men.Journal of the International Association of Providers of AIDS Care, , Volume: 14, Issue:2
THOUGHTS ON PrEP--FROM THE FIRST PERSON CURED OF HIV.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 27, Issue:1
Sexually Transmitted Infections on the Rise in PrEP Users.AIDS reviews, , Volume: 20, Issue:1
More pre-exposure prophylaxis for rising HIV infection?AIDS reviews, , Volume: 16, Issue:2
Treatment options for HIV, AIDS.FDA consumer, , Volume: 38, Issue:6
Knowledge of and interest in using preexposure prophylaxis for HIV prevention among men who have sex with men in Thailand.Journal of the International Association of Providers of AIDS Care, , Volume: 12, Issue:4
A pill to prevent HIV.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 25, Issue:1
New once-a-day drugs: Truvada and Epzicom.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 15, Issue:6
Atypical secondary syphilis presentation in a patient with human immunodeficiency virus infection: a case report.Journal of medical case reports, , Dec-09, Volume: 13, Issue:1, 2019
Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.The Journal of infectious diseases, , May-15, Volume: 213, Issue:10, 2016
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.Journal of acquired immune deficiency syndromes (1999), , Feb-01, Volume: 62, Issue:2, 2013
Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy.Frontiers in public health, , Volume: 11, 2023
Long-acting drug acts like a short-term AIDS vaccine.Science (New York, N.Y.), , 05-22, Volume: 368, Issue:6493, 2020
Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.Journal of acquired immune deficiency syndromes (1999), , 09-01, Volume: 82, Issue:1, 2019
Extensive brain masses and cavitary lung lesions associated with toxoplasmosis and acquired immunodeficiency syndrome.International journal of STD & AIDS, , Volume: 28, Issue:11, 2017
Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.American journal of epidemiology, , Nov-15, Volume: 182, Issue:10, 2015
FDA must publish data on safety and efficacy of prophylactic AIDS drug, court rules.BMJ (Clinical research ed.), , Aug-19, Volume: 347, 2013
PrEP trial successes prompt cost-effectiveness questions.Nature medicine, , Sep-07, Volume: 17, Issue:9, 2011
FDA approves two combo brand-name AIDS drugs.Medicine & health (1997), , Aug-09, Volume: 58, Issue:31, 2004
Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures.The Journal of infectious diseases, , 07-06, Volume: 222, Issue:3, 2020
Mg-supplementation attenuated lipogenic and oxidative/nitrosative gene expression caused by Combination Antiretroviral Therapy (cART) in HIV-1-transgenic rats.PloS one, , Volume: 14, Issue:1, 2019
Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.The Journal of infectious diseases, , May-15, Volume: 213, Issue:10, 2016
Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease.Liver international : official journal of the International Association for the Study of the Liver, , Volume: 35, Issue:4, 2015
Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis.Retrovirology, , May-09, Volume: 9, 2012
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.Expert review of clinical immunology, , Volume: 6, Issue:2, 2010
A truvada hypersensitivity reaction simulating abacavir hypersensitivity.AIDS (London, England), , Oct-18, Volume: 21, Issue:16, 2007
Two-once-daily fixed-dose NRTI combinations for HIV.The Medical letter on drugs and therapeutics, , Feb-28, Volume: 47, Issue:1203, 2005
Comparison of 3-drug versus 4-drug and PI versus non-PI combinations as initial HAART: experience from 1998 to 2007.Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), , Volume: 8, Issue:5
The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.Viruses, , 09-07, Volume: 14, Issue:9, 2022
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.Viruses, , 12-02, Volume: 13, Issue:12, 2021
Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies.Reproductive biomedicine online, , Volume: 33, Issue:2, 2016
Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.Journal of medical case reports, , Sep-28, Volume: 9, 2015
[A needlestick injury - what next?].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
[no title available]Zentralblatt fur Chirurgie, , Volume: 142, Issue:4, 2017
Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies.Reproductive biomedicine online, , Volume: 33, Issue:2, 2016
[A needlestick injury - what next?].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Primary HIV-1 infection in users of pre-exposure prophylaxis.The lancet. HIV, , Volume: 8, Issue:3, 2021
Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.BMC infectious diseases, , Jul-22, Volume: 20, Issue:1, 2020
Some men who were unable to access PrEP through NHS trial are now HIV positive, charities report.BMJ (Clinical research ed.), , Jan-18, Volume: 364, 2019
Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.Journal of acquired immune deficiency syndromes (1999), , 07-01, Volume: 75, Issue:3, 2017
Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies.Reproductive biomedicine online, , Volume: 33, Issue:2, 2016
From modeling to morals: imagining the future of HIV PREP in Lesotho.Developing world bioethics, , Volume: 13, Issue:2, 2013
Recent advances in pre-exposure prophylaxis for HIV.BMJ (Clinical research ed.), , 12-11, Volume: 359, 2017
Preexposure prophylaxis for HIV infection.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
Sexually Transmitted Infections on the Rise in PrEP Users.AIDS reviews, , Volume: 20, Issue:1
Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.PloS one, , Volume: 10, Issue:10, 2015
Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis.The Journal of infectious diseases, , Sep-01, Volume: 206, Issue:5, 2012
Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis.Retrovirology, , May-09, Volume: 9, 2012
Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy.Frontiers in public health, , Volume: 11, 2023
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously Estimated.Health affairs (Project Hope), , Volume: 42, Issue:5, 2023
Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , 01-06, Volume: 76, Issue:1, 2023
HIV Prevention Research Experiences Among Men Who Have Sex With Men and Transgender Persons of Color.Journal of racial and ethnic health disparities, , Volume: 10, Issue:4, 2023
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide.AIDS (London, England), , 12-01, Volume: 36, Issue:15, 2022
The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.Viruses, , 09-07, Volume: 14, Issue:9, 2022
Pill related oesophagitis due to tenofovir disproxil fumarate/emtricitabine (Truvada) HIV pre-exposure prophylaxis.Internal medicine journal, , Volume: 52, Issue:6, 2022
Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.International journal of antimicrobial agents, , Volume: 59, Issue:1, 2022
Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?AIDS patient care and STDs, , Volume: 35, Issue:8, 2021
The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.The Pan African medical journal, , Volume: 38, 2021
Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.Expert opinion on drug safety, , Volume: 20, Issue:11, 2021
Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.Drug testing and analysis, , Volume: 13, Issue:7, 2021
Achilles heel spotted for promising HIV-prevention drug.Nature, , Volume: 591, Issue:7850, 2021
Primary HIV-1 infection in users of pre-exposure prophylaxis.The lancet. HIV, , Volume: 8, Issue:3, 2021
Effect of Truvada lawsuit advertising on preexposure prophylaxis attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV.AIDS (London, England), , 01-01, Volume: 35, Issue:1, 2021
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.Viruses, , 12-02, Volume: 13, Issue:12, 2021
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.Lancet (London, England), , 07-25, Volume: 396, Issue:10246, 2020
Renal impairment: an unnecessary barrier to HIV prevention.Sexual health, , Volume: 17, Issue:3, 2020
Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.Expert opinion on drug metabolism & toxicology, , Volume: 16, Issue:6, 2020
Readability analysis of online health information on preexposure prophylaxis (PrEP).Public health, , Volume: 182, 2020
How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States?Annals of internal medicine, , 05-05, Volume: 172, Issue:9, 2020
The HIV Pre-exposure Prophylaxis (PrEP) Cascade at NYC Sexual Health Clinics: Navigation Is the Key to Uptake.Journal of acquired immune deficiency syndromes (1999), , 04-01, Volume: 83, Issue:4, 2020
Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.CPT: pharmacometrics & systems pharmacology, , Volume: 9, Issue:1, 2020
Atypical secondary syphilis presentation in a patient with human immunodeficiency virus infection: a case report.Journal of medical case reports, , Dec-09, Volume: 13, Issue:1, 2019
Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants.The International journal on drug policy, , Volume: 74, 2019
Piloting a partially self-financed mode of human immunodeficiency virus pre-exposure prophylaxis delivery for men who have sex with men in Hong Kong.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 25, Issue:5, 2019
Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.PloS one, , Volume: 14, Issue:8, 2019
Are 2 million bottles of PrEP an empty gesture?The lancet. HIV, , Volume: 6, Issue:8, 2019
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/Antiviral research, , Volume: 170, 2019
[Progression of STI noted after initiation of EPESE for HIV].Annales de dermatologie et de venereologie, , Volume: 146, Issue:10, 2019
Ethical considerations for new HIV prevention trials.The lancet. HIV, , Volume: 6, Issue:8, 2019
Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.Journal of acquired immune deficiency syndromes (1999), , 09-01, Volume: 82, Issue:1, 2019
HIV preexposure prophylaxis in Canadian primary care and community settings.Canadian family physician Medecin de famille canadien, , Volume: 65, Issue:4, 2019
Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.Pharmacotherapy, , Volume: 39, Issue:4, 2019
Access to HIV Pre-exposure Prophylaxis in Practice Settings: a Qualitative Study of Sexual and Gender Minority Adults' Perspectives.Journal of general internal medicine, , Volume: 34, Issue:4, 2019
Mg-supplementation attenuated lipogenic and oxidative/nitrosative gene expression caused by Combination Antiretroviral Therapy (cART) in HIV-1-transgenic rats.PloS one, , Volume: 14, Issue:1, 2019
Some men who were unable to access PrEP through NHS trial are now HIV positive, charities report.BMJ (Clinical research ed.), , Jan-18, Volume: 364, 2019
Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.PloS one, , Volume: 14, Issue:1, 2019
Experiences of Anticipated and Enacted Pre-exposure Prophylaxis (PrEP) Stigma Among Latino MSM in Los Angeles.AIDS and behavior, , Volume: 23, Issue:7, 2019
Informal PrEP: an emerging need for nomenclature.The Lancet. Public health, , Volume: 4, Issue:2, 2019
Early experience of implementing a national HIV pre-exposure prophylaxis service in Wales, United Kingdom 2017.Sexual health, , Volume: 16, Issue:1, 2019
A Randomized Controlled Pilot Study of a Culturally-Tailored Counseling Intervention to Increase Uptake of HIV Pre-exposure Prophylaxis Among Young Black Men Who Have Sex with Men in Washington, DC.AIDS and behavior, , Volume: 23, Issue:1, 2019
Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.AIDS and behavior, , Volume: 23, Issue:2, 2019
Geographic and Individual Associations with PrEP Stigma: Results from the RADAR Cohort of Diverse Young Men Who have Sex with Men and Transgender Women.AIDS and behavior, , Volume: 22, Issue:9, 2018
Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City.AIDS and behavior, , Volume: 22, Issue:11, 2018
Truvada (emtricitabine/tenofovir) pre-exposure prophylaxis roll-out among South African university students: Lots of positives, but let us keep an eye on possible surprises.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, , Feb-01, Volume: 108, Issue:2, 2018
HIV Prevention Drug's Slow Uptake Undercuts Its Early Promise.Health affairs (Project Hope), , Volume: 37, Issue:2, 2018
The informal use of antiretroviral medications for HIV prevention by men who have sex with men in South Florida: initiation, use practices, medications and motivations.Culture, health & sexuality, , Volume: 20, Issue:11, 2018
Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa.AIDS and behavior, , Volume: 22, Issue:7, 2018
Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.HIV clinical trials, , Volume: 19, Issue:5, 2018
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.The lancet. HIV, , Volume: 5, Issue:11, 2018
Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine.Journal of managed care & specialty pharmacy, , Volume: 24, Issue:10, 2018
Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States.Annals of epidemiology, , Volume: 28, Issue:12, 2018
HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise.Clinical pharmacology and therapeutics, , Volume: 104, Issue:6, 2018
Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.Clinical pharmacology and therapeutics, , Volume: 104, Issue:6, 2018
PrEP and the PrEPstars.The lancet. HIV, , Volume: 5, Issue:11, 2018
Role of Preexposure Prophylaxis in the Reproductive Health of Women at Risk for Human Immunodeficiency Virus Infection.Obstetrics and gynecology, , Volume: 132, Issue:3, 2018
"Free Testing and PrEP without Outing Myself to Parents:" Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men.PloS one, , Volume: 13, Issue:7, 2018
Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.Annals of epidemiology, , Volume: 28, Issue:12, 2018
The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.Annals of epidemiology, , Volume: 28, Issue:12, 2018
How to do it: setting up a PrEP service in an integrated sexual reproductive health service setting.Sexually transmitted infections, , Volume: 94, Issue:5, 2018
Recent advances in pre-exposure prophylaxis for HIV.BMJ (Clinical research ed.), , 12-11, Volume: 359, 2017
Regimen Change: Gilead's TAF Drugs Toppling TDFs in HIV Treatment.Managed care (Langhorne, Pa.), , Volume: 26, Issue:9, 2017
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis.Colombia medica (Cali, Colombia), , Jun-30, Volume: 48, Issue:2, 2017
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.Journal of acquired immune deficiency syndromes (1999), , 12-15, Volume: 76, Issue:5, 2017
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.JAMA pediatrics, , 11-01, Volume: 171, Issue:11, 2017
HIV preexposure prophylaxis for adolescents and young adults.Current opinion in pediatrics, , Volume: 29, Issue:4, 2017
Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.Antimicrobial agents and chemotherapy, , Volume: 61, Issue:7, 2017
Secrecy, empowerment and protection: positioning PrEP in KwaZulu-Natal, South Africa.Culture, health & sexuality, , Volume: 19, Issue:11, 2017
Scotland's approval of PrEP creates postcode lottery in UK, say campaigners.BMJ (Clinical research ed.), , 04-11, Volume: 357, 2017
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).The Journal of antimicrobial chemotherapy, , 06-01, Volume: 72, Issue:6, 2017
Science, technology, power and sex: PrEP and HIV-positive gay men in Paris.Culture, health & sexuality, , Volume: 19, Issue:10, 2017
A case study of chewed TruvadaAntiviral therapy, , Volume: 22, Issue:7, 2017
Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis.Journal of acquired immune deficiency syndromes (1999), , 07-01, Volume: 75, Issue:3, 2017
Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.The New England journal of medicine, , 02-02, Volume: 376, Issue:5, 2017
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.Drug safety, , Volume: 40, Issue:4, 2017
Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men.AIDS and behavior, , Volume: 21, Issue:5, 2017
Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.AIDS and behavior, , Volume: 21, Issue:2, 2017
PrEP on Twitter: Information, Barriers, and Stigma.Health communication, , Volume: 32, Issue:4, 2017
Pre-exposure Prophylaxis in Primary Care--A New Era in HIV Prevention.WMJ : official publication of the State Medical Society of Wisconsin, , Volume: 115, Issue:1, 2016
Feasibility of HIV Pre-Exposure Prophylaxis as Part of Routine Care in Toronto, Canada.Journal of acquired immune deficiency syndromes (1999), , 07-01, Volume: 72, Issue:3, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.Trials, , Mar-24, Volume: 17, 2016
Uncertainty in Online U.S. News Coverage of Truvada.Health communication, , Volume: 31, Issue:10, 2016
[HIV pre-exposure prophylaxis does not increase the rate of STI].Revue medicale suisse, , Jan-27, Volume: 12, Issue:503, 2016
[no title available]Revue medicale suisse, , Aug-10, Volume: 12, Issue:526, 2016
Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.Journal of acquired immune deficiency syndromes (1999), , Apr-01, Volume: 71, Issue:4, 2016
Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?AIDS and behavior, , Volume: 20, Issue:11, 2016
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.PLoS pathogens, , Volume: 12, Issue:1, 2016
ACP Journal Club. Preexposure tenofovir-emtricitabine reduced HIV infection in men who have unprotected anal sex with men.Annals of internal medicine, , Jan-19, Volume: 164, Issue:2, 2016
Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.The Journal of infectious diseases, , May-15, Volume: 213, Issue:10, 2016
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.Clinical pharmacokinetics, , Volume: 55, Issue:7, 2016
The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA.Current opinion in HIV and AIDS, , Volume: 11, Issue:1, 2016
Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.Journal of acquired immune deficiency syndromes (1999), , Apr-01, Volume: 71, Issue:4, 2016
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.Journal of acquired immune deficiency syndromes (1999), , 03-01, Volume: 71, Issue:3, 2016
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.Antiviral therapy, , Volume: 21, Issue:3, 2016
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.Lancet (London, England), , Jan-02, Volume: 387, Issue:10013, 2016
Antiretroviral chemoprophylaxis: PROUD and pragmatism.Lancet (London, England), , Jan-02, Volume: 387, Issue:10013, 2016
PrEP, Truvada, and Gilead.BMJ (Clinical research ed.), , Sep-08, Volume: 354, 2016
Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Expert opinion on drug safety, , Volume: 15, Issue:9, 2016
[EMA examines an application for change in authorization of truvada].MMW Fortschritte der Medizin, , Jun-09, Volume: 158 Suppl 1, 2016
[Protection against HIV - but only with good compliance!].MMW Fortschritte der Medizin, , Jun-09, Volume: 158 Suppl 1, 2016
Guidelines for risk reduction when handling gametes from infectious patients seeking assisted reproductive technologies.Reproductive biomedicine online, , Volume: 33, Issue:2, 2016
Sharing of Investigational Drug Among Participants in the Voice Trial.AIDS and behavior, , Volume: 20, Issue:11, 2016
HIV moments and pre-exposure prophylaxis--Authors' reply.Lancet (London, England), , Apr-09, Volume: 387, Issue:10027, 2016
HIV moments and pre-exposure prophylaxis.Lancet (London, England), , Apr-09, Volume: 387, Issue:10027, 2016
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.AIDS research and therapy, , Volume: 13, 2016
[HIV: France authorizes and fully reimburses Truvada prophylaxis].Revue medicale suisse, , Dec-02, Volume: 11, Issue:497, 2015
[Miscellaneous - profound coma, smoking and AIDS].Revue medicale suisse, , Nov-18, Volume: 11, Issue:495, 2015
HOW DO I PAY FOR PrEP?Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 27, Issue:5, 2015
MOVING FORWARD WITH PrEP. THE BASICS OF PrEP.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 27, Issue:5, 2015
Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.American journal of epidemiology, , Nov-15, Volume: 182, Issue:10, 2015
Invited commentary: every good randomization deserves observation.American journal of epidemiology, , Nov-15, Volume: 182, Issue:10, 2015
Murnane, Coley, and Baeten respond to "every good randomization deserves observation".American journal of epidemiology, , Nov-15, Volume: 182, Issue:10, 2015
Infection: PrEParation to be PROUD of.Nature reviews. Urology, , Volume: 12, Issue:11, 2015
Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.PloS one, , Volume: 10, Issue:10, 2015
Tailoring biomedical interventions for key populations.The lancet. HIV, , Volume: 2, Issue:1, 2015
Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report.Journal of medical case reports, , Sep-28, Volume: 9, 2015
Acute Myocarditis and Myopathy as Presenting Manifestations of Human Immunodeficiency Virus Infection.The Israel Medical Association journal : IMAJ, , Volume: 17, Issue:8, 2015
How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores".American journal of public health, , Volume: 105, Issue:10, 2015
CDC launches prevention efforts focused on PrEP, high-risk groups.AIDS policy & law, , Volume: 30, Issue:6, 2015
[Should pre-exposure prophylaxis be used to prevent HIV?].Revue medicale suisse, , Mar-11, Volume: 11, Issue:465, 2015
Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.Journal of acquired immune deficiency syndromes (1999), , Aug-01, Volume: 69, Issue:4, 2015
Infectious diseases. Doubts dispelled about HIV prevention.Science (New York, N.Y.), , Mar-06, Volume: 347, Issue:6226, 2015
Willingness to Take PrEP and Potential for Risk Compensation Among Highly Sexually Active Gay and Bisexual Men.AIDS and behavior, , Volume: 19, Issue:12, 2015
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.AIDS (London, England), , May-15, Volume: 29, Issue:8, 2015
Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis.Culture, health & sexuality, , Volume: 17, Issue:4, 2015
Miriam Hospital launches new HIV prevention program: PrEP program offers daily pill that can help prevent HIV infection.Rhode Island medical journal (2013), , Volume: 97, Issue:1, 2014
Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.Current HIV/AIDS reports, , Volume: 11, Issue:4, 2014
The medicalization of HIV prevention: new opportunities beset by old challenges.The Milbank quarterly, , Volume: 92, Issue:3, 2014
Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults.The Nurse practitioner, , Sep-18, Volume: 39, Issue:9, 2014
A combination drug for HIV prevention in high-risk groups.The American journal of nursing, , Volume: 114, Issue:8, 2014
The Truvada wars.BMJ (Clinical research ed.), , Jun-24, Volume: 348, 2014
Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.PharmacoEconomics, , Volume: 32, Issue:9, 2014
CDC promotes pre-exposure prophylaxis for HIV prevention.BMJ (Clinical research ed.), , May-19, Volume: 348, 2014
Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 58, Issue:12, 2014
Reply to Sachdev et al.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 58, Issue:12, 2014
Potential HIV prophylaxis enters Canadian pilot trial.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , May-13, Volume: 186, Issue:8, 2014
Uptake of PrEP for HIV slow among MSM.Lancet (London, England), , Feb-01, Volume: 383, Issue:9915, 2014
Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 58, Issue:5, 2014
[HIV prophylaxis kits. A concept for emergency treatment in the context of postexposure prophylaxis].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, , Volume: 85, Issue:1, 2014
From efficacy to impact: an advocate's agenda for HIV pre-exposure prophylaxis implementation.American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Pre-exposure prophylaxis for HIV: who will benefit and what are the challenges?American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Pre-exposure prophylaxis for HIV: can it be implemented in the real world?American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Using registries to monitor HIV pre-exposure prophylaxis safety in clinical settings.American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance.American journal of preventive medicine, , Volume: 44, Issue:1 Suppl 2, 2013
Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand.AIDS care, , Volume: 25, Issue:8, 2013
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.Journal of acquired immune deficiency syndromes (1999), , Feb-01, Volume: 62, Issue:2, 2013
High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.AIDS and behavior, , Volume: 17, Issue:6, 2013
PrEPPING for the future.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
PrEP politics.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
An equal right to protection.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
PrEP in practice.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
PrEP in the real world.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
From professional to personal.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
The new revolution: HIV prevention in a pill.Positively aware : the monthly journal of the Test Positive Aware Network, ,Summer, Volume: 25, Issue:5, 2013
Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.American family physician, , Oct-15, Volume: 88, Issue:8, 2013
[PrEP approved in the USA: facts and discussion - permanent chemoprophylaxis for healthy people].MMW Fortschritte der Medizin, , Jun-13, Volume: 155 Suppl 1, 2013
Emtricitabine + tenofovir to prevent HIV transmission. More evaluation needed.Prescrire international, , Volume: 22, Issue:140, 2013
From modeling to morals: imagining the future of HIV PREP in Lesotho.Developing world bioethics, , Volume: 13, Issue:2, 2013
Research. Approval of Gilead's Truvada for PrEP passes first hurdle at FDA.AIDS policy & law, , Volume: 27, Issue:8, 2012
FDA PrEPares to reduce risk of HIV infection with Truvada®.Expert review of clinical pharmacology, , Volume: 5, Issue:5, 2012
Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.PloS one, , Volume: 7, Issue:12, 2012
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.PloS one, , Volume: 7, Issue:10, 2012
Truvada for HIV prophylaxis in heterosexual patients.JAAPA : official journal of the American Academy of Physician Assistants, , Volume: 25, Issue:10, 2012
A perspective on progress and gaps in HIV prevention science.AIDS research and human retroviruses, , Volume: 28, Issue:11, 2012
Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.Antiviral therapy, , Volume: 17, Issue:6, 2012
HIV pre-exposure prophylaxis.BMJ (Clinical research ed.), , Aug-13, Volume: 345, 2012
In brief: Truvada for HIV prevention.The Medical letter on drugs and therapeutics, , Aug-06, Volume: 54, Issue:1396, 2012
FDA paves the way for pre-exposure HIV prophylaxis.Lancet (London, England), , Jul-28, Volume: 380, Issue:9839, 2012
Ethical challenges of preexposure prophylaxis for HIV.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
Preexposure prophylaxis for HIV infection.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
FDA approves first drug to prevent HIV infection.BMJ (Clinical research ed.), , Jul-17, Volume: 345, 2012
[HIV preexposure prophylaxis].Przeglad epidemiologiczny, , Volume: 66, Issue:1, 2012
How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.The American journal of bioethics : AJOB, , Volume: 12, Issue:6, 2012
AIDS research. FDA panel recommends anti-HIV drug for prevention.Science (New York, N.Y.), , May-18, Volume: 336, Issue:6083, 2012
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Medicinal research reviews, , Volume: 32, Issue:4, 2012
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.AIDS (London, England), , Mar-13, Volume: 26, Issue:5, 2012
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.International journal of STD & AIDS, , Volume: 23, Issue:1, 2012
Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice.Antimicrobial agents and chemotherapy, , Volume: 56, Issue:4, 2012
Great results from iPrEx study add to trifecta of good news on prevention. Truvada PrEP provided protection in MSM+transgender.AIDS alert, , Volume: 26, Issue:1, 2011
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.International journal of clinical practice, , Volume: 65, Issue:12, 2011
HIV drug-prevention strategy carries risks.Nature, , Aug-16, Volume: 476, Issue:7360, 2011
AIDS research. Complexity surrounds HIV prevention advances.Science (New York, N.Y.), , Jul-22, Volume: 333, Issue:6041, 2011
Transmission. Company halts Truvada PrEP for women study.AIDS policy & law, , Volume: 26, Issue:7, 2011
Interim guidance for PrEP in MSM. CDC: Do not expand to other risk groups yet.AIDS alert, , Volume: 26, Issue:4, 2011
Early end for FEM-PrEP HIV prevention trial.AIDS patient care and STDs, , Volume: 25, Issue:6, 2011
HIV prevention trial in women is abandoned after drugs show no impact on infection rates.BMJ (Clinical research ed.), , Apr-20, Volume: 342, 2011
Trial success spurs planning for rollout of HIV prevention pills.Nature medicine, , Volume: 17, Issue:4, 2011
HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.Science (New York, N.Y.), , Dec-03, Volume: 330, Issue:6009, 2010
Still a long wait for approved HIV-protective gel.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, , Sep-07, Volume: 100, Issue:9, 2010
Bioequivalent formulation for the fixed-dose regimen of Truvada and TMC278 finalized.AIDS patient care and STDs, , Volume: 24, Issue:6, 2010
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.Expert review of clinical immunology, , Volume: 6, Issue:2, 2010
Single-tablet Quad regimen achieves high rate of virologic suppression.AIDS patient care and STDs, , Volume: 24, Issue:3, 2010
Second complete once-daily single tablet therapy in development.AIDS patient care and STDs, , Volume: 23, Issue:8, 2009
Truvada and Epivir are similar at suppressing HIV.Project Inform perspective, , Issue:48, 2009
Tapping into combination pills for HIV.Nature reviews. Drug discovery, , Volume: 8, Issue:6, 2009
Generic Truvada approved.AIDS patient care and STDs, , Volume: 23, Issue:5, 2009
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, , Volume: 28, Issue:4, 2009
HIV study yields unexpected preliminary efficacy results.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Apr-15, Volume: 65, Issue:8, 2008
Switching Combivir to Truvada keeps HIV undetectable, improves blood fats, fails to improve limb fat.Project Inform perspective, , Issue:47, 2008
Gay community to test HIV prevention pill.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, , Volume: 98, Issue:9, 2008
Trial will evaluate a once-daily dose of raltegravir.AIDS patient care and STDs, , Volume: 22, Issue:11, 2008
Mexico conference considers pre-exposure prophylaxis for AIDS.BMJ (Clinical research ed.), , Aug-14, Volume: 337, 2008
A truvada hypersensitivity reaction simulating abacavir hypersensitivity.AIDS (London, England), , Oct-18, Volume: 21, Issue:16, 2007
144-week data released on Gilead's study 934.AIDS patient care and STDs, , Volume: 21, Issue:8, 2007
Truvada intolerance.AIDS (London, England), , Jan-30, Volume: 21, Issue:3, 2007
[Simply convincing. New fixed combination for HIV therapy].MMW Fortschritte der Medizin, , Apr-25, Volume: 147 Spec No 1, 2005
[New fixed combination for HIV therapy].Krankenpflege Journal, , Volume: 43, Issue:4-6, 2005
Two-once-daily fixed-dose NRTI combinations for HIV.The Medical letter on drugs and therapeutics, , Feb-28, Volume: 47, Issue:1203, 2005
Emtricitabine/tenofovir disoproxil fumarate.Drugs, , Volume: 64, Issue:18, 2004
Sexually Transmitted Infections on the Rise in PrEP Users.AIDS reviews, , Volume: 20, Issue:1
Treatment options for HIV, AIDS.FDA consumer, , Volume: 38, Issue:6
New once-a-day drugs: Truvada and Epzicom.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 15, Issue:6
PrEP'ing.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 24, Issue:5
Another blue pill for sex: Preventing HIV with Truvada PrEP--already at a pharmacy near you.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 23, Issue:5
Knee avascular necrosis in HIV patient.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 107, Issue:2
THOUGHTS ON PrEP--FROM THE FIRST PERSON CURED OF HIV.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 27, Issue:1
PrEP trial in women halted due to doubts that it could show efficacy.IAVI report : newsletter on international AIDS vaccine research, , Volume: 15, Issue:2
The iPrEx results: lifting hopes, raising questions.BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, , Volume: 22, Issue:4
I Am Men's Health: Generating Adherence to HIV Pre-Exposure Prophylaxis (PrEP) in Young Men of Color Who Have Sex with Men.Journal of the International Association of Providers of AIDS Care, , Volume: 14, Issue:2
Comparison of 3-drug versus 4-drug and PI versus non-PI combinations as initial HAART: experience from 1998 to 2007.Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), , Volume: 8, Issue:5
More pre-exposure prophylaxis for rising HIV infection?AIDS reviews, , Volume: 16, Issue:2
Knowledge of and interest in using preexposure prophylaxis for HIV prevention among men who have sex with men in Thailand.Journal of the International Association of Providers of AIDS Care, , Volume: 12, Issue:4
A pill to prevent HIV.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 25, Issue:1
Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.Internal medicine (Tokyo, Japan), , Volume: 55, Issue:23
Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures.The Journal of infectious diseases, , 07-06, Volume: 222, Issue:3, 2020
Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.The Journal of infectious diseases, , May-15, Volume: 213, Issue:10, 2016
The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge.Science translational medicine, , Jan-14, Volume: 7, Issue:270, 2015
Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.Journal of acquired immune deficiency syndromes (1999), , Aug-01, Volume: 69, Issue:4, 2015
A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.AIDS research and human retroviruses, , Volume: 30, Issue:11, 2014
Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis.Retrovirology, , May-09, Volume: 9, 2012
Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.PloS one, , Volume: 7, Issue:12, 2012
Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis.The Journal of infectious diseases, , Sep-01, Volume: 206, Issue:5, 2012
T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis.PloS one, , Apr-26, Volume: 6, Issue:4, 2011
Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.Journal of virology, , Volume: 85, Issue:15, 2011
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.Science translational medicine, , Jan-13, Volume: 2, Issue:14, 2010
[no title available]Zentralblatt fur Chirurgie, , Volume: 142, Issue:4, 2017
[A needlestick injury - what next?].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
[HIV prophylaxis kits. A concept for emergency treatment in the context of postexposure prophylaxis].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, , Volume: 85, Issue:1, 2014
Safety/Toxicity (8)
| Article | Year |
|---|
Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
International journal of antimicrobial agents, , Volume: 59, Issue:1 | 2022 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Antiviral research, , Volume: 170 | 2019 |
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
JAMA pediatrics, , 11-01, Volume: 171, Issue:11 | 2017 |
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
Drug safety, , Volume: 40, Issue:4 | 2017 |
Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
Expert opinion on drug safety, , Volume: 15, Issue:9 | 2016 |
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
Journal of acquired immune deficiency syndromes (1999), , 03-01, Volume: 71, Issue:3 | 2016 |
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
International journal of clinical practice, , Volume: 65, Issue:12 | 2011 |
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, , Volume: 28, Issue:4 | 2009 |
Pharmacokinetics (2)
Bioavailability (2)
| Article | Year |
|---|
The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.
Viruses, , 09-07, Volume: 14, Issue:9 | 2022 |
Comparative bioavailability of two tablet formulations of emtricitabine/tenofovir in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
International journal of clinical pharmacology and therapeutics, , Volume: 54, Issue:10 | 2016 |
Dosage (9)
| Article | Year |
|---|
Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
Journal of acquired immune deficiency syndromes (1999), , 09-01, Volume: 82, Issue:1 | 2019 |
Recent advances in pre-exposure prophylaxis for HIV.
BMJ (Clinical research ed.), , 12-11, Volume: 359 | 2017 |
Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.
Journal of acquired immune deficiency syndromes (1999), , 07-01, Volume: 75, Issue:3 | 2017 |
The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge.
Science translational medicine, , Jan-14, Volume: 7, Issue:270 | 2015 |
A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.
AIDS research and human retroviruses, , Volume: 30, Issue:11 | 2014 |
Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.
PloS one, , Volume: 7, Issue:12 | 2012 |
High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.
AIDS and behavior, , Volume: 17, Issue:6 | 2013 |
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.
Science translational medicine, , Jan-13, Volume: 2, Issue:14 | 2010 |
Two-once-daily fixed-dose NRTI combinations for HIV.
The Medical letter on drugs and therapeutics, , Feb-28, Volume: 47, Issue:1203 | 2005 |
Interactions (2)